X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (145) 145
life sciences & biomedicine (142) 142
humans (111) 111
oncology (97) 97
male (73) 73
middle aged (60) 60
carcinoma, renal cell - drug therapy (54) 54
female (54) 54
kidney neoplasms - drug therapy (51) 51
aged (49) 49
metastasis (44) 44
kidney neoplasms - pathology (43) 43
renal cell carcinoma (43) 43
urology & nephrology (43) 43
cancer (41) 41
adult (38) 38
carcinoma, renal cell (34) 34
treatment outcome (31) 31
antineoplastic agents - therapeutic use (29) 29
care and treatment (29) 29
prognosis (29) 29
carcinoma, renal cell - pathology (27) 27
life sciences (26) 26
neoplasm metastasis (25) 25
urology (25) 25
disease-free survival (24) 24
hematology, oncology and palliative medicine (24) 24
tumors (23) 23
carcinoma, renal cell - secondary (22) 22
kidney cancer (22) 22
aged, 80 and over (20) 20
immunotherapy (20) 20
patients (20) 20
sunitinib (20) 20
vascular endothelial growth factor (20) 20
clear cell-type renal cell carcinoma (19) 19
metastases (19) 19
analysis (18) 18
clinical trials (17) 17
molecular targeted therapy (17) 17
retrospective studies (17) 17
chemotherapy (16) 16
clinical medicine (16) 16
klinisk medicin (16) 16
medical and health sciences (16) 16
medicin och hälsovetenskap (16) 16
prostate cancer (16) 16
urology and nephrology (16) 16
young adult (16) 16
urologi och njurmedicin (14) 14
antineoplastic agents (13) 13
antineoplastic combined chemotherapy protocols - therapeutic use (13) 13
kidney neoplasms - genetics (13) 13
metastatic renal cell carcinoma (13) 13
protein kinase inhibitors - therapeutic use (13) 13
risk factors (13) 13
survival (13) 13
antimitotic agents (12) 12
carcinoma, renal cell - genetics (12) 12
everolimus (12) 12
kaplan-meier estimate (12) 12
kidney neoplasms - metabolism (12) 12
medical research (12) 12
prospective studies (12) 12
animals (11) 11
carcinoma, renal cell - metabolism (11) 11
survival rate (11) 11
targeted therapy (11) 11
[sdv]life sciences [q-bio] (10) 10
antineoplastic agents - adverse effects (10) 10
axitinib (10) 10
health aspects (10) 10
neoplasm staging (10) 10
receptors, vascular endothelial growth factor - antagonists & inhibitors (10) 10
time factors (10) 10
urologic and male genital diseases (10) 10
cancer therapies (9) 9
carcinoma, renal cell - surgery (9) 9
drug therapy (9) 9
immune checkpoint (9) 9
medicine, experimental (9) 9
nephrectomy (9) 9
niacinamide - analogs & derivatives (9) 9
nivolumab (9) 9
pharmacology & pharmacy (9) 9
toxicity (9) 9
tyrosine (9) 9
[sdv.can]life sciences [q-bio]/cancer (8) 8
abridged index medicus (8) 8
angiogenesis (8) 8
apoptosis (8) 8
carcinoma, renal cell - mortality (8) 8
kidney neoplasms - mortality (8) 8
kidney neoplasms - surgery (8) 8
patient outcomes (8) 8
pd-l1 protein (8) 8
proportional hazards models (8) 8
prostatic neoplasms, castration-resistant - drug therapy (8) 8
research (8) 8
survival analysis (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Science (American Association for the Advancement of Science), ISSN 1095-9203, 01/2018, Volume 359, Issue 6371, pp. 91 - 97
Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis induce sustained clinical responses in a sizable minority of cancer patients. We found that... 
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | CD4 Antigens - immunology | Immunotherapy - methods | Humans | Antibodies, Monoclonal - therapeutic use | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Gastrointestinal Microbiome - genetics | Fecal Microbiota Transplantation | Anti-Bacterial Agents - therapeutic use | Feces - microbiology | Metagenome - genetics | Neoplasms - therapy | Animals | Receptors, CCR - immunology | Interleukin-12 - immunology | Receptors, CXCR3 - immunology | T-Lymphocytes - immunology | Mice | Gastrointestinal Microbiome - immunology | Verrucomicrobia - genetics | Verrucomicrobia - immunology | Care and treatment | Cell receptors | Microbiota (Symbiotic organisms) | Immunotherapy | Epithelial tumors | Physiological aspects | Health aspects | Methods | Apoptosis | PD-1 protein | Interleukin | Microbiomes | Transplantation | Lymphocytes T | Anticancer properties | Microbiota | Lymphocytes | Bacteria | Feces | Supplementation | Gnotobiotics | Kidneys | Melanoma | Dietary supplements | Interleukin 12 | Abundance | CXCR3 protein | Patients | CD4 antigen | Immune checkpoint | Antibiotics | Lungs | Flora | PD-L1 protein | Relative abundance | Antitumor activity | CCR9 protein | Tumors | Kidney transplantation | Cancer | Index Medicus | Life Sciences
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 03/2019, Volume 380, Issue 12, pp. 1103 - 1115
Journal Article
The New England journal of medicine, ISSN 1533-4406, 08/2018, Volume 379, Issue 5, pp. 417 - 427
Journal Article
European urology, ISSN 0302-2838, 08/2015, Volume 68, Issue 2, pp. 228 - 235
Abstract Background Cabazitaxel, abiraterone acetate (AA), and enzalutamide have been approved for the treatment of patients with metastatic... 
Urology | Metastatic | Abiraterone | Prostate cancer | Cabazitaxel | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Phenylthiohydantoin - adverse effects | Phenylthiohydantoin - therapeutic use | Humans | Middle Aged | Receptors, Androgen - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Molecular Targeted Therapy | Prostatic Neoplasms, Castration-Resistant - pathology | Dose-Response Relationship, Drug | Taxoids - therapeutic use | Receptors, Androgen - drug effects | Time Factors | Aged, 80 and over | Kallikreins - blood | Retrospective Studies | France | Taxoids - adverse effects | Cell Survival - drug effects | Androstenes - adverse effects | Kaplan-Meier Estimate | Androstenes - therapeutic use | Treatment Outcome | Prostatic Neoplasms, Castration-Resistant - drug therapy | Prostatic Neoplasms, Castration-Resistant - metabolism | Phenylthiohydantoin - analogs & derivatives | Prostate-Specific Antigen - blood | Disease-Free Survival | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Androgen Antagonists - therapeutic use | Cell Line, Tumor | Aged | Cell Proliferation - drug effects | Prostatic Neoplasms, Castration-Resistant - mortality | Androgen Antagonists - adverse effects | Index Medicus
Journal Article